These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31147887)

  • 21. Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.
    Pishko GL; Muldoon LL; Pagel MA; Schwartz DL; Neuwelt EA
    Fluids Barriers CNS; 2015 Feb; 12():5. PubMed ID: 25879723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between micro-computed tomography angiography and dynamic contrast enhanced MRI.
    Kim E; Kim J; Maelandsmo GM; Johansen B; Moestue SA
    Magn Reson Med; 2017 Oct; 78(4):1513-1522. PubMed ID: 27888545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravoxel Incoherent Motion Combined With Dynamic Contrast-Enhanced Perfusion MRI of Early Cervical Carcinoma: Correlations Between Multimodal Parameters and HIF-1α Expression.
    Li X; Wu S; Li D; Yu T; Zhu H; Song Y; Meng L; Fan H; Xie L
    J Magn Reson Imaging; 2019 Sep; 50(3):918-929. PubMed ID: 30648775
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Wang Y; Liu H; Yao D; Li J; Yang S; Zhang C; Chen W; Wang D
    J Nanobiotechnology; 2019 Oct; 17(1):105. PubMed ID: 31604441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DCE-MRI-Derived Parameters in Evaluating Abraxane-Induced Early Vascular Response and the Effectiveness of Its Synergistic Interaction with Cisplatin.
    Sun X; Yang L; Yan X; Sun Y; Zhao D; Ji Y; Wang K; Chen X; Shen B
    PLoS One; 2016; 11(9):e0162601. PubMed ID: 27632532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
    Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
    Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
    Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC
    Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway.
    Lu N; Hui H; Yang H; Zhao K; Chen Y; You QD; Guo QL
    Eur J Pharm Sci; 2013 May; 49(2):220-6. PubMed ID: 23501055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.
    Chen YF; Yuan A; Cho KH; Lu YC; Kuo MY; Chen JH; Chang YC
    PLoS One; 2017; 12(11):e0187824. PubMed ID: 29121075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of tumor radioresponsiveness and metastatic potential by dynamic contrast-enhanced magnetic resonance imaging.
    Øvrebø KM; Gulliksrud K; Mathiesen B; Rofstad EK
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):255-61. PubMed ID: 21816291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.
    Greening DW; Lee ST; Ji H; Simpson RJ; Rigopoulos A; Murone C; Fang C; Gong S; O'Keefe G; Scott AM
    Oncotarget; 2015 Nov; 6(35):38166-80. PubMed ID: 26517691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring the therapeutic efficacy of CA4P in the rabbit VX2 liver tumor using dynamic contrast-enhanced MRI.
    Han T; Duan Q; Yang R; Wang Y; Yin H; Meng F; Liu Y; Qian T
    Diagn Interv Radiol; 2021 Sep; 27(5):587-594. PubMed ID: 34559047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative dynamic contrast-enhanced magnetic resonance imaging in a VX2 rabbit liver tumour model using different gadolinium-based contrast agents: comparison of DCE-MRI quantitative results between Magnevist and Eovist.
    Zhang Y; Liu H; Xiao W; Zhu L; Wang N; He X; Jiang Z; Guan B
    BJR Case Rep; 2017; 3(3):20160099. PubMed ID: 30363268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
    Kim E; Tunset HM; Cebulla J; Vettukattil R; Helgesen H; Feuerherm AJ; Engebråten O; Mælandsmo GM; Johansen B; Moestue SA
    BMC Cancer; 2016 Mar; 16():191. PubMed ID: 26951085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy.
    Cheng L; Liu W; Zhong C; Ni P; Ni S; Wang Q; Zhang Q; Zhang J; Liu J; Xu M; Yao X; Cen X; Wang G; Jiang C; Zhou F
    J Ethnopharmacol; 2021 Apr; 270():113770. PubMed ID: 33388426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
    Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
    NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
    Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
    Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic contrast-enhanced perfusion parameters in ovarian cancer: Good accuracy in identifying high HIF-1α expression.
    Lindgren A; Anttila M; Rautiainen S; Arponen O; Hämäläinen K; Könönen M; Vanninen R; Sallinen H
    PLoS One; 2019; 14(8):e0221340. PubMed ID: 31437208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.
    Chen BB; Lu YS; Lin CH; Chen WW; Wu PF; Hsu CY; Yu CW; Wei SY; Cheng AL; Shih TT
    BMC Cancer; 2016 Jul; 16():466. PubMed ID: 27412562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantification of antiangiogenic treatment effects on tissue heterogeneity in glioma tumour xenograft model using a combination of DCE-MRI and 3D-ultramicroscopy.
    Dominietto M; Dobosz M; Bürgi S; Renner A; Zahlmann G; Scheuer W; Rudin M
    Eur Radiol; 2017 Jul; 27(7):2894-2902. PubMed ID: 27830379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.